Chapter 142 Chronic Hepatitis Therapy

  1. Andersson M, Sevelius E: Breed, sex and age distribution in dogs with chronic liver disease: a demographic study, J Small Anim Pract 32:1, 1991.
  2. Bexfield NH et al: Breed, age and gender distribution of dogs with chronic hepatitis in the United Kingdom, Vet J 193:124, 2012. PUBMED Abstract
  3. Friedman SL: Evolving challenges in hepatic fibrosis, Nat Rev Gastroenterol Hepatol 7:425, 2010. PUBMED Abstract
  4. Jarrett WF, O'Neil BW: A new transmissible agent causing acute hepatitis, chronic hepatitis and cirrhosis in dogs, Vet Rec 116:629, 1985. PUBMED Abstract
  5. Luo W et al: Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat, PlosOne 7:e34230, 2012. PUBMED Abstract
  6. Poldervaart JH et al: Primary hepatitis in dogs: a retrospective review (2002-2006), J Vet Intern Med 23:72, 2009. PUBMED Abstract
  7. Raffan E et al: Ascites is a negative prognostic indicator in chronic hepatitis in dogs, J Vet Intern Med 23:63, 2009. PUBMED Abstract
  8. Strombeck DR, Miller LM, Harrold D: Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977-1985), J Am Vet Med Assoc 9:1109, 1988. PUBMED Abstract
  9. Watson PJ: Canine chronic liver disease: a review of current understanding of the aetiology, progression and treatment of chronic liver disease in the dog, Vet J 167:228, 2004.
  10. Watson PJ et al: Prevalence of hepatic lesions at post-mortem examination in dogs and association with pancreatitis, J Small Anim Pract 51:566, 2010. PUBMED Abstract
  11. WSAVA Liver Standardization Group: WSAVA standards for clinical and histological diagnosis of canine and feline liver diseases, ed 1, Philadelphia, 2006, Saunders-Elsevier.